Navigation Links
Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer
Date:5/22/2013

PALO ALTO, Calif., May 22, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved half of the enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer. To date the trial has had no Severe Adverse Effect (SAE) reported.

The Phase I clinical trial for TC-DC therapy for HCC, registered with NIH under number NCT01828762 (click here to view) is an open label clinical trial conducted with Shanghai's PLA 85 Hospital, one of the Liver Disease Centers of People's Liberation Army. The trial will evaluate the safety and efficacy in lowering the incidence of tumor recurrence and metastasis by means of autologous immune cell therapy in primary HCC patients following standard tumor resection and TACE chemotherapy.

Cellular Biomedicine Group's VP and GM of the Autologous Products Business Unit, Cheng Xiang (Chase) Dai, MD, commented, "We expect that enrollment will progress quickly and this study is on schedule to complete Phase I clinical trials."

Hepatocellular Carcinoma
Forty-five percent of the world's HCC patients are in China, with over 300,000 new patients diagnosed every year. Currently the therapies commonly offered to most patients are surgery and local chemotherapy, with a 2-year recurrence rate of 51% and median survival time of 13 months.

The TC-DC therapy that CBMG is developing has had extraordinary US phase II metastatic melanoma trial results, with a 5 year overall survival of 54% in the TC-DC group versus 10% in the control group, and a median survival time of 4.5 years for the TC-DC group, versus 1.3 years for the control group with standard therapies.

"TC-DC therapy takes a sample of the patient's own dendritic cells, the 'trainer' cells of effecter immune cells, and a sample of the patient's tumor stem cells, and co-cultures them together in the lab. The dendritic cells will learn the characteristics of the patient's own tumor stem cells, and are reintroduced to the patient's body as a vaccine, where they can 'train' the immune system to fight and destroy the tumor stem cells, which are the root cause of tumor recurrence and metastasis," explained Dr. William Cao , President of CBMG. "We are excited about the potential of this therapy to not only extend life but to maintain a high quality of life by not subjecting the patient to dramatic chemotherapy and its adverse effects."

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit:www.cellbiomedgroup.com

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contact:
Jeff Ramson 
Investor Relations
ProActive Capital Group
+1 646-863-6341

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 650 566 5064
sarah.kelly@cellbiomedgroup.com

 


'/>"/>
SOURCE Cellular Biomedicine Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellular Dynamics Launches MyCell™ Services
2. Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell Technologies
3. CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells
4. EastBridge Investment Group Announces Merger with Cellular Biomedicine Group
5. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
6. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
7. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
8. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
9. Cellular Biomedicine Group Marks the Launch of China Clinical Trial for TC-DC Therapy for Hepatocellular Carcinoma
10. Cellular Dynamics International Opens Facility in California, Leasing Space from the Buck Institute to Derive and Bank Human Induced Pluripotent Stem Cells
11. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... PUNE, India , April 29, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" market research report ... pipeline, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology company built ... Dr. Alfredo Zurlo as Chief Medical Officer. ... years clinical experience and a proven track record in ... at Mologen AG where he was Chief Medical Officer ... held various positions at F Hoffmann La Roche and ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
Breaking Medicine Technology:
(Date:5/2/2016)... , ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) ... at Manhattan College, made the cut. The WUGC is being held in London, England this ... the gold in the men’s division, another gold in the women’s masters division, and a ...
(Date:5/2/2016)... ... , ... Pregnancy Awareness Month offers a great time to get familiar with ... are ready to have a baby, it’s best to get started before age becomes ... Personal Conception & Pregnancy Organizer, written for women who plan on becoming pregnant to ...
(Date:5/2/2016)... ... May 02, 2016 , ... A ... completed two groundbreaking studies that determined that the adjustability and adaptability of pediatric ... the prevention of pressure injuries, which are now referred to as “pressure injuries” ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) ... B Payment Model Could Transform the Pharma Landscape .” CMS recently proposed a test ... spend on provider-administered drugs while preserving care provided to beneficiaries. The webinar will review ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Evolve Paddle Board Company- ... prices announced today the outcome of their partnership with Yoloha Yoga- producers of high ... Yoga Board.” , SUP yoga has seen a dramatic rise in popularity throughout the ...
Breaking Medicine News(10 mins):